Lupus patients are not getting sick from CCP virus

[UsualName]

For your review before you jump on the Remsdivir band wagon.

https://www.marketwatch.com/amp/story/guid/F857E1C4-A254-47D4-8B87-04955D4FC31A

Three days ago the Chinese government made all clinical trials related to Covid send in a justification for their study. They ended up cutting most studies as they are claiming they now have low infection rates and the studies are not needed.

You also made a comment about some people wanting a treatment to fail. I am currently smack dab in the middle of one of the worst Covid outbreaks in the world. No one wants an effective treatment more than me. What doesn’t help is misinformation.

Just because chloroquine doesn’t appear to be effective in late stage illness in one study does not mean it cannot be effective in combination therapies or in earlier stage illness.

The goal here is to get to the best information possible to make informed decisions. For example, two weeks ago it was all about ventilatiors now doctors are less inclined to use them and are focusing on patient positioning and oxygen through cpap machines because the outcome was so bad for ventilators.

We have to be able to move and not get stuck on what we thought might work when outcomes are not proving effectiveness.

 

[TreeFrogTrader]

For your review before you jump on the Remsdivir band wagon.

https://www.marketwatch.com/amp/story/guid/F857E1C4-A254-47D4-8B87-04955D4FC31A

Yeh, well trump people and others should not talk to me using the term "cures" nor should you or others be cautioning me about "joining bandwagons." I think my lengthy post outlined a totally different approach and disposition. I am just following developments. and said that I will adjust my view as the results develop.

However, I did not exactly see what the big caution is over resdemsivir. The article is saying that the studies are small and it is early in the review. Well, duh.

Otherwise, yes, I will be following it. but no joining bandwagons. Along with several other drugs and treatment methods - just as I said in my post.

From the article:

Analysts say early data showing Gilead Sciences Inc.’s remdesivir improved clinical outcomes for two-thirds of a small group of severely ill COVID-19 patients is promising, but they caution against viewing the experimental drug as a silver bullet in the fight against the novel coronavirus.

The data showed that 68% of 53 hospitalized patients showed clinical improvement after taking the drug. It’s a “promising first look

 

[Dr. Love]

Yeh, well trump people and others should not talk to me using the term "cures" nor should you or others be cautioning me about "joining bandwagons." I think my lengthy post outlined a totally different approach and disposition. I am just following developments. and said that I will adjust my view as the results develop.

However, I did not exactly see what the big caution is over resdemsivir. The article is saying that the studies are small and it is early in the review. Well, duh.

Otherwise, yes, I will be following it. but no joining bandwagons. Along with several other drugs and treatment methods - just as I said in my post.

From the article:

Analysts say early data showing Gilead Sciences Inc.’s remdesivir improved clinical outcomes for two-thirds of a small group of severely ill COVID-19 patients is promising, but they caution against viewing the experimental drug as a silver bullet in the fight against the novel coronavirus.

The data showed that 68% of 53 hospitalized patients showed clinical improvement after taking the drug. It’s a “promising first look

Pardon me, not knocking Remsdivir, just noting that it might not be the best med to take if trials are being cancelled.

 

[TreeFrogTrader]

Pardon me, not knocking Remsdivir, just noting that it might not be the best med to take if trials are being cancelled.

Did you actually read the article that you posted?

It said the chinese had cancelled clinical trials in two studies because the chinese could not find participants because they or the people felt that the covid situation was under control. That is probably bullshiite but that is what the stated reason was- not side effects or poor outcomes from earlier trials.

And then the article ended on the positive note that I quoted above, but I will post it again. In any case there are several other remsdivir studies going on so whether the chinese are participating or not is of no interest to me. In fact, I am decidedly not interest in ANYTHING chinese these days.

From the article:

Analysts say early data showing Gilead Sciences Inc.’s remdesivir improved clinical outcomes for two-thirds of a small group of severely ill COVID-19 patients is promising, but they caution against viewing the experimental drug as a silver bullet in the fight against the novel coronavirus.

The data showed that 68% of 53 hospitalized patients showed clinical improvement after taking the drug. It’s a “promising first look

 

[UsualName]

More good news on remdesivir:

https://amp.cnn.com/cnn/2020/04/16/...ir-trial/index.html?__twitter_impression=true

 

[gwb-trading]

Stocks signal big rally Friday on Gilead’s coronavirus treatment and Boeing’s production restart
https://www.foxbusiness.com/markets/stock-futures-april-16

Its drug Remdesivir, according to Statnews.com, showed effectiveness for treating COVID-19 patients. Shares of Gilead rose over 10 percent in the extended session.

A recent clinical trial of Remdesivir, an antiviral medicine used as a potential treatment for Ebola, found rapid recoveries in coronavirus patients' fever and respiratory symptoms.

The trial, conducted by the University of Chicago Medicine, found nearly all patients who were given daily infusions of Remdesivir were discharged from the hospital in less than a week.

 

[Bugenhagen]

I was talking to a local nurse and she reported an undoubtedly fast stabilisation of a patient given a Covid-19 recovered antibody transfusion from a family member.

Not a surprise but good to hear.

 

[Dr. Love]

Did you actually read the article that you posted?

It said the chinese had cancelled clinical trials in two studies because the chinese could not find participants because they or the people felt that the covid situation was under control. That is probably bullshiite but that is what the stated reason was- not side effects or poor outcomes from earlier trials.

And then the article ended on the positive note that I quoted above, but I will post it again. In any case there are several other remsdivir studies going on so whether the chinese are participating or not is of no interest to me. In fact, I am decidedly not interest in ANYTHING chinese these days.

From the article:

Analysts say early data showing Gilead Sciences Inc.’s remdesivir improved clinical outcomes for two-thirds of a small group of severely ill COVID-19 patients is promising, but they caution against viewing the experimental drug as a silver bullet in the fight against the novel coronavirus.

The data showed that 68% of 53 hospitalized patients showed clinical improvement after taking the drug. It’s a “promising first look

This is the part I was referring from the same article.

"Evercore ISI analyst Umer Raffat told investors in a note on Wednesday that the large number of trials initiated in China to find a treatment for the disease may have made it difficult to find enough participants. However, he also noted that: "We can't ignore the fact that if remdesivir had overwhelming efficacy, trials may have enrolled."

 

[TreeFrogTrader]

This is the part I was referring from the same article.

"Evercore ISI analyst Umer Raffat told investors in a note on Wednesday that the large number of trials initiated in China to find a treatment for the disease may have made it difficult to find enough participants. However, he also noted that: "We can't ignore the fact that if remdesivir had overwhelming efficacy, trials may have enrolled."

There is a reason why Gilead's stock spiked based on leaked data results. The fact that the article speculated that it may not have "overwhelming efficacy" is neither here nor there. As I have said- probably close to six times now- this will be a game of stacking small edges together to improve treatment outcomes so any drug that can contribute to that will be seen as having potentiel. Those who are looking for a knock-out drug or cure will see no value.

Meanwhile. I have said that I will follow resdemisvir along with several other developments and I see no reason to not to that or to be less optimistic about resdemisivar. So far it shows an edge- although not overwhelmingly major. I am following hydroxy/ zpac as well and it's data is rather shaky- despite your advocacy for it- and that is fine. If it presents a valuable edge I will continue to look at it as the studies unfold. If it does not. Well, then fortunately there are several other developments. I am not married to anything.

 

[ids]

From https://www.sermo.com

Globally 17% Point Increase in COVID Treaters Who Have Used Hydroxychloroquine (33%-50%) and Azithromycin (41%-58%)

Percentage of New York Physicians Who Have Used Hydroxychloroquine Nearly Doubled, Italian and French Physicians Jumped 30% Points + Over 2 Weeks

Plasma Still Perceived as Most Effective but Not Widely Used

Perception of Hydroxychloroquine’s Efficacy is Significantly Higher Among Physicians in Europe and China vs US Physicians (50% vs 29%)